ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Takeda concludes sale of select OTC and non-core assets to Hypera Pharma
February 01, 2021Takeda Pharmaceutical Company announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. for a total value of $825 million. This divestment agreement was first announced in March 2020. -
Takeda Divests Assets to Hypera for $825M
March 03, 2020Portfolio includes OTC and prescription pharmaceutical products from Takeda's Growth & Emerging Markets BU.
Pharma Sources Insight January 2025
